At White House forum, Bertagnolli, Califf, Wegrzyn call for greater innovation in clinical trials

Eric Green leaves his job as director of the NIH National Human Genome Research Institute

After serving as the director of the National Human Genome Research Institute for more than 15 years, Eric Green has left his role.

March 21, 2025

Vol.51 No.11

Clinical Roundup

Elahere shows survival benefit in long-term analysis for ovarian cancer patients in phase III study

AbbVie announced the final analysis of the confirmatory phase III MIRASOL trial evaluating the efficacy and safety of Elahere in women with folate receptor alpha-positive platinum-resistant ovarian cancer compared to chemotherapy.

March 21, 2025

Vol.51 No.11

Clinical Roundup

Genmab’s Rina-S shows promise in treating advanced ovarian cancer

Genmab A/S announced on March 17 updated data from cohort B1 of the phase I/II RAINFOL-01 study of rinatabart sesutecan, an investigational folate receptor-alpha-targeted, TOPO1 antibody-drug conjugate that showed Rina-S 120 mg/m2 every three weeks resulted in a confirmed objective response rate of 55.6% (95% CI: 30.8-78.5) in heavily pre-treated ovarian cancer patients regardless of FRα expression levels.

March 21, 2025

Vol.51 No.11

Clinical Roundup

Immunovia completes second clinical validation of next-gen pancreatic cancer test

Immunovia announced results from the VERIFI study, the second clinical validation study of its next-generation pancreatic cancer test.

March 21, 2025

Vol.51 No.11

Drugs & Targets

FDA approves Keytruda combination for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)

FDA granted traditional approval to Merck’s pembrolizumab (Keytruda) with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (CPS ≥1).

March 21, 2025

Vol.51 No.11

Podcast

In the Headlines: Could “flooding the zone” drown NIH and cancer centers?

With a growing backlog at NIH and Columbia University’s grants getting canceled over alleged antisemitism, where does that leave NCI-designated cancer centers?

March 19, 2025

Vol.51 No.10

At White House forum, Bertagnolli, Califf, Wegrzyn call for greater innovation in clinical trials

YOU MAY BE INTERESTED IN

Eric Green leaves his job as director of the NIH National Human Genome Research Institute

Elahere shows survival benefit in long-term analysis for ovarian cancer patients in phase III study

Genmab’s Rina-S shows promise in treating advanced ovarian cancer

Immunovia completes second clinical validation of next-gen pancreatic cancer test

FDA approves Keytruda combination for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)

In the Headlines: Could “flooding the zone” drown NIH and cancer centers?

Renew today!

Subscriber content

Never miss an issue!

Login

At White House forum, Bertagnolli, Califf, Wegrzyn call for greater innovation in clinical trials

YOU MAY BE INTERESTED IN

Eric Green leaves his job as director of the NIH National Human Genome Research Institute

Elahere shows survival benefit in long-term analysis for ovarian cancer patients in phase III study

Genmab’s Rina-S shows promise in treating advanced ovarian cancer

Immunovia completes second clinical validation of next-gen pancreatic cancer test

FDA approves Keytruda combination for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)

In the Headlines: Could “flooding the zone” drown NIH and cancer centers?

Never miss an issue!

Login

FDA approves Keytruda combination for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)